within Pharmacolibrary.Drugs.ATC.M;

model M05BA07
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.006,
    Cl             = 0.0018,
    adminDuration  = 600,
    adminMass      = 30 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.013800000000000002,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.022833333333333334,
    Tlag           = 0,            
    Vdp             = 0.0389,
    k12             = 21.2,
    k21             = 21.2
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>M05BA07</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Risedronic acid (risedronate) is a bisphosphonate drug used to strengthen bone, treat or prevent osteoporosis, and manage other bone diseases such as Paget's disease. It is approved and widely used today for prevention and treatment of osteoporosis in postmenopausal women, to increase bone mass in men with osteoporosis, and to treat or prevent glucocorticoid-induced osteoporosis.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers, both male and female, after single oral administration.</p><h4>References</h4><ol><li><p>Licata, AA (1997). Bisphosphonate therapy. <i>The American journal of the medical sciences</i> 313(1) 17–22. DOI:<a href=&quot;https://doi.org/10.1097/00000441-199701000-00004&quot;>10.1097/00000441-199701000-00004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9001162/&quot;>https://pubmed.ncbi.nlm.nih.gov/9001162</a></p></li><li><p>Goa, KL, &amp; Balfour, JA (1998). Risedronate. <i>Drugs &amp; aging</i> 13(1) 83–92. DOI:<a href=&quot;https://doi.org/10.2165/00002512-199813010-00008&quot;>10.2165/00002512-199813010-00008</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9679211/&quot;>https://pubmed.ncbi.nlm.nih.gov/9679211</a></p></li><li><p>Liberman, UA (2006). Long-term safety of bisphosphonate therapy for osteoporosis: a review of the evidence. <i>Drugs &amp; aging</i> 23(4) 289–298. DOI:<a href=&quot;https://doi.org/10.2165/00002512-200623040-00002&quot;>10.2165/00002512-200623040-00002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16732688/&quot;>https://pubmed.ncbi.nlm.nih.gov/16732688</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end M05BA07;
